Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 4/20 | 0.52 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 10/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633930 | 0.87 | PAK4 (0.44) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL13633950 | 0.86 | PAK4 (0.46) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL4511804 | 0.85 | ALDH1A1 (0.44) | PAK4PLK4ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4515170 | 0.82 | PAK4 (0.44) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL4513602 | 0.79 | PAK4 (0.45) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL4527070 | 0.78 | PAK4 (0.41) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL13633968 | 0.77 | PAK4 (0.40) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL10267511 | 0.76 | AURKA (0.53) | PAK4PLK4NTRK1AURKAAURKB | |
| SCHEMBL4529635 | 0.76 | PAK4 (0.42) | PAK4PLK4PAK1JAK2NTRK1 | |
| SCHEMBL4524538 | 0.76 | IGF1R (0.50) | PAK4PLK4PAK1JAK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | PAK4 3321/4885PLK4 999/4885PAK1 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.